---
generator: Riched20 10.0.19041

High-Intensity Focused Ultrasound (HIFU) in Tumor Therapy

Submitted by: Mohamed Roshdy El-Sayed\
Student, Department of Radiology and Medical Imaging\
Faculty of Applied Health Science Technology\
Delta University

Abstract

High-Intensity Focused Ultrasound (HIFU) is a non-invasive cancer therapy that relies on precisely focused acoustic energy to ablate malignant and benign tissues. Compared with conventional modalities, HIFU demonstrates reduced morbidity, minimal invasiveness, and retreatability. This research integrates global evidence, success rates, complications, and compares HIFU against surgery and radiotherapy, while also addressing the Egyptian context where HIFU remains limited but promising.

Keywords: HIFU, tumor ablation, focused ultrasound, prostate cancer, fibroids, Egypt

Introduction

Figure: Clinical HIFU Device

Cancer therapy has traditionally relied on surgery, chemotherapy, and radiotherapy. While effective, these modalities often entail significant morbidity. High-Intensity Focused Ultrasound (HIFU) emerged as an innovative non-invasive approach that uses converging ultrasound waves to generate localized heat, inducing coagulative necrosis in tumor tissue. HIFU is used in prostate cancer, uterine fibroids, and explored in liver, pancreas, and breast tumors.

Literature Review

Several clinical trials and observational studies demonstrate the safety and efficacy of HIFU. Meta-analyses of focal HIFU for prostate cancer show cancer-specific survival at 90--100% in 10 years, with continence preservation exceeding 95%. For uterine fibroids, MR-guided HIFU shows volume reductions up to 59% with symptom improvement. Palliative use in pancreatic cancer provides pain relief in 60--85% of cases.

Figures

Figure 1. Schematic of HIFU system.

Figure 2. Workflow of HIFU treatment.

Figure 3. Example of a clinical HIFU device (Focal One / MRgHIFU).
MRgHIFU: Non-invasive precision ultrasound and MRI technology

As you can see in this figure, the MRgHIFU system combines focused ultrasound with MRI for precise tumor therapy

Success Rates and Complications

Indication	Outcome	Results	Source
Prostate cancer (focal)	Oncologic & functional	90--100% 10y survival; continence \~97%	Yang 2024; Guang 2024
Prostate cancer	Complications	ED 16.7%; Retention 6.2%; UTI 3.0%; Incontinence 1.9%	Peretsman 2024
Fibroids (MRgFUS)	Adverse events	24.7% overall (mostly mild); major 0.41%	Kociuba 2023
Fibroids (US-guided)	Volume reduction	\~59% reduction at 1 year	Dohmen 2024
Pancreatic cancer	Pain relief	60--85% relief	Liu 2025

Comparison: HIFU vs Surgery vs Radiotherapy

Aspect	HIFU	Surgery (RP)	Radiotherapy
Invasiveness	Non-invasive, outpatient	Invasive, hospital stay	Non-invasive, multiple sessions
Incontinence	\~1--3%	\~6--25%	Lower early; late UI possible
Erectile dysfunction	\~15--30%	35--80%	Up to 50%
Oncologic control	Good mid-term	Excellent long-term	Excellent long-term

Local Context: Egypt

In Egypt, HIFU adoption remains scarce. The first Egyptian and North African MRgHIFU experience for fibroids was published in 2024, proving feasibility and safety. Barriers include cost, MRI availability, trained personnel, and reimbursement limitations. Despite these challenges, Egypt holds potential for pioneering research on HIFU applications.**Discussion**

The evidence base for HIFU is growing, especially in prostate cancer and uterine fibroids. While complication rates are lower than surgery or radiotherapy, long-term oncologic control still requires validation in randomized controlled trials. In Egypt, limited infrastructure remains a key barrier, yet the technology aligns with the trend toward non-invasive, patient-centered oncology.

Conclusion

HIFU is a transformative, non-invasive technique with strong safety and functional benefits. Further large-scale trials and investment in infrastructure are needed for integration in Egypt. Nonetheless, it represents a promising alternative and adjunct to conventional oncology treatments.

References

• Guang ZLP et al., 2024. Eur Urol Oncol.

• Yang CH et al., 2024. MDPI Reviews.

• Peretsman SJ et al., 2024. Meta-analysis.

• Kociuba J et al., 2023. JTU.

• Dohmen S et al., 2024. Eur Radiol.

• Liu Y et al., 2025. SciDirect.

• Egyptian Journal of Radiology & Nuclear Medicine, 2024 (First Egyptian MRgHIFU).